-
1
-
-
77952890912
-
Natural history of central retinal vein occlusion: An evidence-based systematic review
-
McIntosh RL, Rogers SL, Lim L, et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(6):1113–1123.e15.
-
(2010)
Ophthalmology
, vol.117
, Issue.6
-
-
McIntosh, R.L.1
Rogers, S.L.2
Lim, L.3
-
2
-
-
0029842865
-
Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study
-
Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol. 1996;114:1243–1247.
-
(1996)
Arch Ophthalmol
, vol.114
, pp. 1243-1247
-
-
Mitchell, P.1
Smith, W.2
Chang, A.3
-
3
-
-
75149172639
-
The prevalence of retinal vein occlusion: Pooled data from population studies from the United States, Europe, Asia, and Australia
-
Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313–319.
-
(2010)
Ophthalmology
, vol.117
, Issue.2
, pp. 313-319
-
-
Rogers, S.1
McIntosh, R.L.2
Cheung, N.3
-
4
-
-
84942796059
-
-
The Royal College of Ophthalmology, Accessed July 17, 2015
-
The Royal College of Ophthalmology. Interim guidelines for management of retinal vein occlusion. Available from: https://www.rcophth.ac.uk/wp-content/uploads/2014/12/2010-SCI-095-RVO-Interim-Guidelines-Dec-2010-FINAL.pdf. Accessed July 17, 2015.
-
Interim Guidelines for management of Retinal Vein Occlusion
-
-
-
5
-
-
77952889477
-
CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: Six-month primary end point results of a phase III study
-
Brown DM, Campochiaro PA, Singh RP, et al; CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1124–1133.
-
(2010)
Ophthalmology
, vol.117
, Issue.6
, pp. 1124-1133
-
-
Brown, D.M.1
Campochiaro, P.A.2
Singh, R.P.3
-
6
-
-
84867100215
-
BRAVO and CRUISE Study Groups. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: Results from the BRAVO and CRUISE trials
-
Varma R, Bressler NM, Suñer I, et al; BRAVO and CRUISE Study Groups. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology. 2012;119(10):2108–2118.
-
(2012)
Ophthalmology
, vol.119
, Issue.10
, pp. 2108-2118
-
-
Varma, R.1
Bressler, N.M.2
Suñer, I.3
-
7
-
-
84862817252
-
Ranibizumab for macular edema due to retinal vein occlusions: Long-term follow-up in the HORIZON trial
-
Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119(4):802–809.
-
(2012)
Ophthalmology
, vol.119
, Issue.4
, pp. 802-809
-
-
Heier, J.S.1
Campochiaro, P.A.2
Yau, L.3
-
8
-
-
84891631064
-
RETAIN Study Group. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: The RETAIN study
-
Campochiaro PA, Sophie R, Pearlman J, et al; RETAIN Study Group. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014;121(1):209–219.
-
(2014)
Ophthalmology
, vol.121
, Issue.1
, pp. 209-219
-
-
Campochiaro, P.A.1
Sophie, R.2
Pearlman, J.3
-
9
-
-
84908658307
-
GALILEO Study Group. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study
-
Ogura Y, Roider J, Korobelnik JF, et al; GALILEO Study Group. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol. 2014;158(5):1032–1038.
-
(2014)
Am J Ophthalmol
, vol.158
, Issue.5
, pp. 1032-1038
-
-
Ogura, Y.1
Roider, J.2
Korobelnik, J.F.3
-
10
-
-
84903819352
-
Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: Two-year results from the COPERNICUS study
-
Heier JS, Clark WL, Boyer DS, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014;121(7):1414–1420.
-
(2014)
Ophthalmology
, vol.121
, Issue.7
, pp. 1414-1420
-
-
Heier, J.S.1
Clark, W.L.2
Boyer, D.S.3
-
11
-
-
80052857441
-
Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results
-
Haller JA, Bandello F, Belfort R Jr, et al; Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118(12):2453–2460.
-
(2011)
Ophthalmology
, vol.118
, Issue.12
, pp. 2453-2460
-
-
Haller, J.A.1
Bandello, F.2
Belfort, R.3
-
12
-
-
84904395653
-
-
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion. NICE technology appraisal guidance. TA229, July 2011
-
National Institute for Health and Care Excellence. Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion. NICE technology appraisal guidance. TA229, July 2011. Available from: https://www.nice.org.uk/guidance/ta229. Accessed July 17, 2015.
-
National Institute for Health and Care Excellence
-
-
-
13
-
-
84904395653
-
-
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion. NICE technology appraisal guidance. TA283, May 2013
-
National Institute for Health and Care Excellence. Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion. NICE technology appraisal guidance. TA283, May 2013. Available from: https://www.nice.org.uk/guidance/ta283. Accessed July 17, 2015.
-
National Institute for Health and Care Excellence
-
-
-
14
-
-
84904395653
-
-
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion. NICE technology appraisal guidance. TA305, February 2014
-
National Institute for Health and Care Excellence. Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion. NICE technology appraisal guidance. TA305, February 2014. Available from: https://www.nice.org.uk/guidance/ta305. Accessed July 17, 2015.
-
National Institute for Health and Care Excellence
-
-
-
15
-
-
36448993366
-
Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): Results of the Pan-American Collaborative Retina Study Group (PACORES)
-
Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al; Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246(1):81–87.
-
(2008)
Graefes Arch Clin Exp Ophthalmol
, vol.246
, Issue.1
, pp. 81-87
-
-
Wu, L.1
Martínez-Castellanos, M.A.2
Quiroz-Mercado, H.3
-
16
-
-
34247231034
-
Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion
-
Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2007;27(4):419–425.
-
(2007)
Retina
, vol.27
, Issue.4
, pp. 419-425
-
-
Rabena, M.D.1
Pieramici, D.J.2
Castellarin, A.A.3
Nasir, M.A.4
Avery, R.L.5
-
17
-
-
84870708962
-
Benefit from bevacizumab for macular edema in central retinal vein occlusion: Twelve-month results of a prospective, randomized study
-
Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology. 2012;119(12):2587–2591.
-
(2012)
Ophthalmology
, vol.119
, Issue.12
, pp. 2587-2591
-
-
Epstein, D.L.1
Algvere, P.V.2
Von Wendt, G.3
Seregard, S.4
Kvanta, A.5
-
18
-
-
84892595664
-
Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion
-
Hikichi T, Higuchi M, Matsushita T, et al. Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol. 2014;98(2):195–199.
-
(2014)
Br J Ophthalmol
, vol.98
, Issue.2
, pp. 195-199
-
-
Hikichi, T.1
Higuchi, M.2
Matsushita, T.3
-
19
-
-
77954759614
-
Novel method for analyzing Snellen visual acuity measurements
-
Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing Snellen visual acuity measurements. Retina. 2010;30(7):1046–1050.
-
(2010)
Retina
, vol.30
, Issue.7
, pp. 1046-1050
-
-
Gregori, N.Z.1
Feuer, W.2
Rosenfeld, P.J.3
-
21
-
-
84937738744
-
A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1
-
Narayanan R, Panchal B, Das T, Chhablani J, Jalali S, Ali MH; MARVEL Study Group. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1. Br J Ophthalmol. January 28, 2015.
-
(2015)
Br J Ophthalmol
, pp. 28
-
-
Narayanan, R.1
Panchal, B.2
Das, T.3
Chhablani, J.4
Jalali, S.5
Ali, M.H.6
-
22
-
-
84905090578
-
Intravitreal ranibizumab for retinal vein occlusion through 1 year in clinical practice
-
Brynskov T, Kemp H, Sørensen TL. Intravitreal ranibizumab for retinal vein occlusion through 1 year in clinical practice. Retina. 2014;34(8):1637–1643.
-
(2014)
Retina
, vol.34
, Issue.8
, pp. 1637-1643
-
-
Brynskov, T.1
Kemp, H.2
Sørensen, T.L.3
-
23
-
-
84893473269
-
Testing the effectiveness of intravitreal ranibizumab during 12 months of follow-up in venous occlusion treatment
-
Pacella E, Pacella F, La Torre G, et al. Testing the effectiveness of intravitreal ranibizumab during 12 months of follow-up in venous occlusion treatment. Clin Ther. 2012;163(6):e413–e422.
-
(2012)
Clin Ther
, vol.163
, Issue.6
-
-
Pacella, E.1
Pacella, F.2
La Torre, G.3
-
24
-
-
84886430519
-
IVAN Study Investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularization: 2-year findings of the IVAN randomized controlled trial
-
Chakravarthy U, Harding SP, Rogers CA, et al; IVAN Study Investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularization: 2-year findings of the IVAN randomized controlled trial. Lancet. 2013;382(9900):1258–1267.
-
(2013)
Lancet
, vol.382
, Issue.9900
, pp. 1258-1267
-
-
Chakravarthy, U.1
Harding, S.P.2
Rogers, C.A.3
-
25
-
-
84863320414
-
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results
-
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388–1398.
-
(2012)
Ophthalmology
, vol.119
, Issue.7
, pp. 1388-1398
-
-
Martin, D.F.1
Maguire, M.G.2
Fine, S.L.3
-
26
-
-
84888643134
-
Intravitreal anti-VEGF therapy for choroidal neovascularization secondary to pathological myopia: 4-year outcome (with CATT and IVAN)
-
Ruiz-Moreno JM, Arias L, Montero JA, Carneiro A, Silva R. Intravitreal anti-VEGF therapy for choroidal neovascularization secondary to pathological myopia: 4-year outcome (with CATT and IVAN). Br J Ophthalmol. 2013;97(11):1447–1450.
-
(2013)
Br J Ophthalmol
, vol.97
, Issue.11
, pp. 1447-1450
-
-
Ruiz-Moreno, J.M.1
Arias, L.2
Montero, J.A.3
Carneiro, A.4
Silva, R.5
-
27
-
-
84882254907
-
A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema
-
Nepomuceno AB, Takaki E, Paes de Almeida FP, et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. Am J Ophthalmol. 2013;156(3):502–510.e2.
-
(2013)
Am J Ophthalmol
, vol.156
, Issue.3
-
-
Nepomuceno, A.B.1
Takaki, E.2
De Paes Almeida, F.P.3
-
28
-
-
84866598095
-
The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: An indirect comparison in a systematic review (with IVAN and CATT)
-
Ford JA, Elders A, Shyangdan D, Royle P, Waugh N. The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review (with IVAN and CATT). BMJ. 2012;345:e5182.
-
(2012)
BMJ
, vol.345
-
-
Ford, J.A.1
Elders, A.2
Shyangdan, D.3
Royle, P.4
Waugh, N.5
-
29
-
-
84925423332
-
Comparative effectiveness randomized clinical trial of aflibercept, bevacizumab, or ranibizumab for diabetic macular edema, protocol T
-
Retinopathy Clinical Research Network
-
Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, et al. Comparative effectiveness randomized clinical trial of aflibercept, bevacizumab, or ranibizumab for diabetic macular edema, protocol T. N Engl J Med. 2015;372:1193–1203.
-
(2015)
N Engl J Med
, vol.372
, pp. 1193-1203
-
-
Wells, J.A.1
Glassman, A.R.2
Ayala, A.R.3
-
30
-
-
84920748073
-
Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol
-
Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015;122(1):146–152.
-
(2015)
Ophthalmology
, vol.122
, Issue.1
, pp. 146-152
-
-
Berg, K.1
Pedersen, T.R.2
Sandvik, L.3
Bragadóttir, R.4
-
31
-
-
84940390831
-
Neovascular events in eyes with central retinal vein occlusion undergoing serial bevacizumab or ranibizumab intravitreal injections: A retrospective review
-
DeCroos FC, Todorich B, Alshareef R, et al. Neovascular events in eyes with central retinal vein occlusion undergoing serial bevacizumab or ranibizumab intravitreal injections: a retrospective review. J Ophthalmic Vis Res. 2014;9(4):461–468.
-
(2014)
J Ophthalmic Vis Res
, vol.9
, Issue.4
, pp. 461-468
-
-
Decroos, F.C.1
Todorich, B.2
Alshareef, R.3
|